Cargando…
Current pharmacotherapy of overactive bladder
Overactive bladder is a symptom complex consisting of bothersome storage urinary symptoms that is highly prevalent among both sexes and has a significant impact on quality of life. Various antimuscarinic agents and the beta-3 agonists mirabegron and vibegron are currently available for the treatment...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Urologia
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486454/ https://www.ncbi.nlm.nih.gov/pubmed/34003613 http://dx.doi.org/10.1590/S1677-5538.IBJU.2021.99.12 |
_version_ | 1784577741642792960 |
---|---|
author | Kreydin, Evgenyi I. Gomes, Cristiano M. Cruz, Francisco |
author_facet | Kreydin, Evgenyi I. Gomes, Cristiano M. Cruz, Francisco |
author_sort | Kreydin, Evgenyi I. |
collection | PubMed |
description | Overactive bladder is a symptom complex consisting of bothersome storage urinary symptoms that is highly prevalent among both sexes and has a significant impact on quality of life. Various antimuscarinic agents and the beta-3 agonists mirabegron and vibegron are currently available for the treatment of OAB. Each drug has specific pharmacologic properties, dosing schedule and tolerability profile, making it essential to individualize the medical treatment for the patient's characteristics and expectations. In this manuscript, we review the most important factors involved in the contemporary pharmacological treatment of OAB. |
format | Online Article Text |
id | pubmed-8486454 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Sociedade Brasileira de Urologia |
record_format | MEDLINE/PubMed |
spelling | pubmed-84864542021-10-03 Current pharmacotherapy of overactive bladder Kreydin, Evgenyi I. Gomes, Cristiano M. Cruz, Francisco Int Braz J Urol Review Article Overactive bladder is a symptom complex consisting of bothersome storage urinary symptoms that is highly prevalent among both sexes and has a significant impact on quality of life. Various antimuscarinic agents and the beta-3 agonists mirabegron and vibegron are currently available for the treatment of OAB. Each drug has specific pharmacologic properties, dosing schedule and tolerability profile, making it essential to individualize the medical treatment for the patient's characteristics and expectations. In this manuscript, we review the most important factors involved in the contemporary pharmacological treatment of OAB. Sociedade Brasileira de Urologia 2021-05-10 /pmc/articles/PMC8486454/ /pubmed/34003613 http://dx.doi.org/10.1590/S1677-5538.IBJU.2021.99.12 Text en https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Kreydin, Evgenyi I. Gomes, Cristiano M. Cruz, Francisco Current pharmacotherapy of overactive bladder |
title | Current pharmacotherapy of overactive bladder |
title_full | Current pharmacotherapy of overactive bladder |
title_fullStr | Current pharmacotherapy of overactive bladder |
title_full_unstemmed | Current pharmacotherapy of overactive bladder |
title_short | Current pharmacotherapy of overactive bladder |
title_sort | current pharmacotherapy of overactive bladder |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486454/ https://www.ncbi.nlm.nih.gov/pubmed/34003613 http://dx.doi.org/10.1590/S1677-5538.IBJU.2021.99.12 |
work_keys_str_mv | AT kreydinevgenyii currentpharmacotherapyofoveractivebladder AT gomescristianom currentpharmacotherapyofoveractivebladder AT cruzfrancisco currentpharmacotherapyofoveractivebladder |